Zacks Investment Research on MSN11d
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, ...
J&J gets FDA Fast Track status for nipocalimab in Sjogren's
Johnson & Johnson (NYSE:JNJ) said on Tuesday that it received U.S. FDA's Fast Track designation for nipocalimab to treat adult patients with moderate-to-severe Sjögren's disease. In November last year ...
Morningstar7d
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
FDA Fast Track Designation is a regulatory mechanism intended to expedite the development and approval of new drugs. This designation facilitates interaction and communication with FDA throughout ...
Healio12d
Nipocalimab nets FDA fast-track designation for Sjögren’s disease
The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...
Fast Company5d
Here’s what to know about Blujepa, the new FDA-approved UTI treatment heading to market this year
The Food and Drug Administration (FDA) has approved a new drug ... The final deadline for Fast Company’s Best Workplaces for Innovators Awards is this Friday, March 28, at 11:59 p.m. PT.
CURE9d
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
Yahoo Finance7d
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative ...